Aficamten vs Mavacamten
Aficamten: Discovery and Phase 3 Insights vs. Mavacamten in Hypertrophic Cardiomyopathy
From discovery to clinical development, aficamten outperforms mavacamten in PK, safety, and therapeutic margin. SEQUOIA-HCM, MAPLE-HCM, and ongoing ACACIA-HCM highlight its potential in obstructive and non-obstructive HCM.